scholarly journals Population-nosological research biobank of the National Medical Research Center for Therapy and Preventive Medicine: analysis of biosamples, principles of collecting and storing information

2022 ◽  
Vol 20 (8) ◽  
pp. 3119
Author(s):  
O. V. Kopylova ◽  
A. I. Ershova ◽  
M. S. Pokrovskaya ◽  
A. N. Meshkov ◽  
I. A. Efimova ◽  
...  

Aim. To analyze the structure of clinical data, as well as the principles of collecting and storing related data of the biobank of the National Medical Research Center for Therapy and Preventive Medicine (hereinafter Biobank).Material and methods. The analysis was carried out using the documentation available in the Biobank, as well as the databases used in its work. The paper presents clinical data on biosamples available in the Biobank as of August 18, 2021.Results. At the time of analysis, the Biobank had 373547 samples collected from 54192 patients within 37 research projects. The article presents the analysis of data representation and quantitative assessment of the presence/absence of common diagnoses in clinical projects. Approaches to documenting clinical information associated with biological samples stored in the Biobank were assessed. The methods and tools used for standardization and automation of processes used in the Biobank were substantiated.Conclusion. The Biobank of the National Medical Research Center for Therapy and Preventive Medicine is the largest research biobank in Russia, which meets all modern international requirements and is one of the key structures that improve the research quality and intensify their conduct both within the one center and in cooperation with other biobanks and scientific institutions. The collection and systematic storage of clinical abstracts of biological samples is an integral and most important part of the Biobank’s work.

2021 ◽  
Vol 20 (7) ◽  
pp. 2960
Author(s):  
O. M. Drapkina ◽  
E. A. Poddubskaya ◽  
V. B. Rozanov ◽  
L. G. Gasanova

Aim. To assess the influence of sex, age and length of service on scientific productivity (h-index in the RSCI, Scopus and Web of Science) of researchers of the National Medical Research Center for Therapy and Preventive Medicine.Material and methods. The study sample was formed from the staff of the National Medical Research Center for Therapy and Preventive Medicine and consisted of scientists of various ranks. The study included 147 people (women, 103; men, 44); Information was collected on their age, education, length of service, academic degree, the position held and author-level metrics  — the h-index, obtained from three abstract and citation databases  — RSCI, Scopus and Web of Science. All study participants were divided into groups by sex and age categories — young (≤39 years), middle-aged (men, 40-60 years; women, 40-55 years) and older (men >60 years old; women >55 years).Results. Analysis showed that 70,1% of the research team consists of women; 60%  — young and middle-aged scientists, and 40%  — older people. Among male researchers, compared with women, there are more doctors of science and high h-index values in the RSCI, Scopus and Web of Science. H-index value in the RSCI among male researchers is 47,3% due to the age and work duration at the National Medical Research Center for Therapy and Preventive Medicine, and among female researchers, 42,8% due to academic degree and length of service. The h-index in Scopus in men is influenced by age, in women  — by the presence of an academic degree, which explain, respectively, 19,7 and 18,1% of its variability. H-index value in the Web of Science in men is associated with the work duration, while in women, with an academic degree and length of service, which explain, respectively, 24,4 and 21,1% of its variance.Conclusion. Women and young and middle-aged scientists prevail in research team pattern of the National Medical Research Center for Therapy and Preventive Medicine. However, male researchers make a more significant contribution to scientific productivity, assessed by the h-index in the RSCI, Scopus and Web of Science. Age and length of service have the greatest influence on scientific productivity for male researchers, while for women — presence of academic degree and length of service. It is necessary to continue research on the study of individual, motivational and institutional factors affecting the scientific productivity.


2022 ◽  
Vol 20 (8) ◽  
pp. 3043
Author(s):  
N. V. Gnennaya ◽  
S. V. Timofeeva ◽  
A. O. Sitkovskaya ◽  
I. A. Novikova ◽  
I. B. Lysenko ◽  
...  

Aim. To create a collection of samples of blood components of patients with multiple myeloma for potential fundamental and applied biomedical research.Material and methods. The material was collected according to the developed algorithm, including the collection of clinical information, biological material, sample preparation, quality control and storage in the biobank of the National Medical Research Center of Oncology.Results. As of August 2021, the cryostorage of the National Medical Research Center of Oncology biobank contains a collection of 175 samples of blood serum, plasma and mononuclear cell fraction of patients with multiple myeloma. Samples were obtained from 32 patients of both sexes, the mean age of which was 59,5±1,65 years. To create an electronic catalog, personal, clinical and laboratory data about patients were collected, after which each sample was assigned its own unique identification number. Written informed consent was obtained from all patients for the storage of their biomaterial in a biobank with possible subsequent use for scientific purposes. Freezing of the obtained samples was carried out in accordance with low-temperature storage protocol. The electronic catalog contains a wide range of systematized clinical and laboratory information on samples.Conclusion. The collection of multiple myeloma samples is a unique resource for potential research on its pathophysiology, the development of diagnostic biomarkers, and the search for targeted agents.


2020 ◽  
Vol 23 (6) ◽  
pp. 7
Author(s):  
O.M. Drapkina ◽  
R.N. Shepel ◽  
T.V. Vakhovskaya ◽  
L.M. Zhamalov ◽  
A.V. Kutcher ◽  
...  

2020 ◽  
Vol 19 (6) ◽  
pp. 2741
Author(s):  
I. V. Samokhina ◽  
A. B. Sagakyants

Aim. To present the main results and changes in the work of the biobank of the National Medical Research Center of Oncology during the pandemic of coronavirus disease 2019 (COVID-19).Material and methods. The paper presents a dynamic analysis of the delivery of fresh frozen biological samples from operated patients for three quarters of 2019 and 2020, as well as considers possible ways to implement research projects to collect and deposit materials for the biobank within the COVID-19 pandemic. The work included persons over 18 years old, with primary gastrointestinal cancers, who, upon hospitalization, gave informed consent to transfer biological material tothe biobank. One of the inclusion criteria was the presence of a negative nasopharyngeal swabs tested for SARS-CoV-2 by the polymerase chain reaction. Data calculation and comparative analysis of the results was carried out using the Microsoft Office Excel software package.Results. It was revealed that in the first quarter of 2019, 34% of biological samples were received from the total amount for the year, while in 2020 — 50%; in the second quarter of 2019 — 35%. The second quarter of 2020 was characterized by change in the schedule of work of institutions due to the COVID-19 pandemic, which led to a 56% decrease in the number of samples compared to the same period in 2019 and amounted to 14% of material collected for the three quarters of2020. In the third quarter of 2020, the flow was restored and amounted to 65 patients, which corresponds to 36% of material collected in this year and is more than in 2019 by 23%.Conclusion. a critical decrease in the deposited material in the second quarter of 2020 indicated the need to adapt the current biobanking rules inRussia in general and the studied biobank in particular. Possible adaptation ways may consist in the creation of joint projects between groups of scientists from different organizations, taking into account the requirements of information and biological safety. This problem and ways to solve it were widely discussed at international and Russian platforms, including the 4th meeting of the National Association of Biobanks and Biobanking Specialists, dedicated to the organization of biobanking during the COVID-19 pandemic.


2018 ◽  
Vol 64 (3) ◽  
pp. 388-393
Author(s):  
Yekaterina Anokhina ◽  
V. Rubinchik ◽  
Yekaterina Yaremenko ◽  
Gulfiya Teletaeva ◽  
Dilorom Latipova ◽  
...  

Ipilimumab (IPI) provides a ten-year overall survival in almost 20 % of selected patients participated in several phase II-III trials. However, the expanded access program (EAP) looks more like routine practice than like clinical trials& This is why the results of such application could be different. Here we present the long-term follow-up data of single center EAP. Ninety-six patients with disseminated melanoma progressing after at least one lines of drug therapy were included at the N.N. Petrov National Medical Research Center of Oncology. Sixty-seven (70 %) patients had stage IV M1c, 35 patients (36 %) had elevated LDH before initiating IPI therapy. All patients received IPI 3 mg / kg IV every 3 weeks for a maximum of 4 cycles. Totally, 320 cycles (mean - 3.3 per patient) were conducted. Grade 3-4 immuno-mediated adverse events (imAE) observed in 18 (19 %) patients. Three patients died of adverse events, possibly associated with ongoing therapy. The median time to progression was 3 (95 % CI, 2.4 to 3.5) mo., the median overall survival was 13 (95 % CI, 8.3 to17.6) mo. Previous immunotherapy with dendritic cell vaccines decreased the risk of death by 48 % (Log-rank p = 0.049). The wild type BRAF status increased three-year overall survival from 29 to 68 % (p = 0.042). Our data confirms long-term safety and efficacy of IPI in patients with pretreated disseminated melanoma in the close to real practice setting.


2020 ◽  
Vol 19 (4) ◽  
pp. 20-31
Author(s):  
E. A. Litvin ◽  
D. T. Utalieva ◽  
D. Yu. Kachanov ◽  
A. V. Pshonkin ◽  
M. Ya. Yadgarov ◽  
...  

13-cis-Retinoic acid is a differentiation agent for neuroblastoma cells and is a part of post-consolidation therapy for high-risk patients. The effectiveness of this therapeutic approach is currently under study. 26 patients with high-risk neuroblastoma treated at Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology were included in the study of 13-cis-Retinoic acid pharmacokinetics by high-performance liquid chromatography assay with ultraviolet detector depending on the method of administration of drug (swallowed capsules or opened capsules before administration). This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The current study showed that the therapeutic concentration of > 2 μM when taking 13-cis-Retinoic acid at a dose of 160 mg/m2/day was achieved in two groups, regardless of the method of drug administration. However, plasma concentrations of 13-cis-Retinoic acid at 4 hours after administration on the 14th day of therapy were higher in the group of patients who swallowed the capsules (4.1 ± 1.8 μM), compared to those who could not do it (1.9 ± 1.5 μM) (p = 0.022). The introduction into the clinical practice of therapeutic drug monitoring of 13-cis-retinoic acid in high-risk neuroblastoma patients with an assessment of peak concentration and dose adjustment of the following courses may be an important point in the attempt to optimize postconsolidation therapy and improve prognosis.


Sign in / Sign up

Export Citation Format

Share Document